Celcuity: Phase 3 Breakthrough Sets Stage for Potential Blockbuster in Breast Cancer – High Risk, High Reward Ahead
Overview
Celcuity Inc. is a clinical-stage biotechnology company focused on developing innovative targeted therapies for solid tumors, with gedatolisib as its lead candidate for HR+/HER2- breast cancer. In 2025, groundbreaking Phase 3 trial results showed a 76% reduction in disease progression risk, positioning gedatolisib as a potential new standard of care. With an NDA filing planned by late 2025 and a vast addressable market, Celcuity is poised for a dramatic transition from R&D to commercialization, supported by strong clinical data and ample cash reserves.